Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Patient-specific tumor-associated antigens presented on MHC (Major Histocompatibility Complex), commonly referred to as patient-specific neoantigens or tumor-specific antigens (TSAs) presented on MHC, represent a highly personalized class of therapeutic targets in oncology. These antigens arise from somatic mutations unique to an individual patient's tumor, such as single-nucleotide variants, frameshifts, or insertions/deletions, which are processed intracellularly and presented as short peptides on the cell surface by MHC class I or class II molecules. Because these neoantigens are absent in normal tissues, they are not subject to central immune tolerance, making them highly immunogenic and ideal targets for precision immunotherapy.
Therapeutic strategies targeting these patient-specific pMHC complexes include individualized neoantigen therapies (INTs), such as personalized mRNA- or peptide-based cancer vaccines (e.g., intismeran autogene and autogene cevumeran), as well as adoptive cell therapies like TCR-engineered T cells. Upon administration, these vaccines prompt antigen-presenting cells to display the selected neoantigens on their MHC molecules, priming and expanding a de novo repertoire of CD8+ cytotoxic T cells and CD4+ helper T cells. These activated T cells then selectively recognize and destroy tumor cells presenting the corresponding patient-specific antigens, minimizing off-target toxicities. However, the clinical efficacy of targeting these antigens can be limited by tumor-mediated downregulation of MHC expression, mutations in antigen-processing machinery, and the logistical challenges of rapid, patient-specific vaccine manufacturing.
Individualized neoantigen therapies or personalized cancer vaccines deliver genetic material or peptides encoding patient-specific neoantigens. These are taken up by antigen-presenting cells, processed, and presented on MHC class I and class II molecules. This presentation activates and expands patient-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, which then migrate to the tumor microenvironment, recognize the same neoantigens presented on the tumor cells' MHC, and selectively lyse the cancer cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Patient-specific tumor-associated antigens presented on MHC (Patient-specific TAA-MHC).